Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Consensus Rating of "Moderate Buy" from Brokerages

Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the five research firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $43.60.

Several research analysts recently weighed in on the stock. Piper Sandler decreased their price objective on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating on the stock in a research report on Tuesday, February 4th. HC Wainwright restated a "buy" rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. Needham & Company LLC reaffirmed a "buy" rating and set a $46.00 price objective on shares of Collegium Pharmaceutical in a report on Wednesday, April 9th. Finally, StockNews.com downgraded Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Saturday, April 19th.

Collegium Pharmaceutical Price Performance

Collegium Pharmaceutical stock traded up $0.01 during midday trading on Wednesday, reaching $26.79. 214,645 shares of the stock were exchanged, compared to its average volume of 443,364. Collegium Pharmaceutical has a 52 week low of $23.23 and a 52 week high of $42.29. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. The firm has a market cap of $860.82 million, a PE ratio of 11.55 and a beta of 0.76. The company's fifty day moving average is $28.46 and its 200-day moving average is $30.87.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.09. The firm had revenue of $181.95 million for the quarter, compared to analysts' expectations of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. On average, sell-side analysts forecast that Collegium Pharmaceutical will post 5.62 EPS for the current year.

Insiders Place Their Bets

In related news, EVP Shirley R. Kuhlmann sold 26,067 shares of the company's stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $28.50, for a total transaction of $742,909.50. Following the completion of the sale, the executive vice president now directly owns 108,137 shares in the company, valued at $3,081,904.50. This represents a 19.42 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Colleen Tupper sold 10,445 shares of the stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $30.01, for a total transaction of $313,454.45. Following the sale, the chief financial officer now directly owns 165,246 shares of the company's stock, valued at $4,959,032.46. The trade was a 5.95 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 81,693 shares of company stock valued at $2,334,994 over the last three months. Insiders own 2.51% of the company's stock.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several institutional investors and hedge funds have recently bought and sold shares of the business. New Age Alpha Advisors LLC purchased a new stake in Collegium Pharmaceutical in the fourth quarter worth $40,000. Wealthquest Corp bought a new stake in shares of Collegium Pharmaceutical during the 1st quarter valued at about $62,000. KBC Group NV increased its position in shares of Collegium Pharmaceutical by 72.5% during the fourth quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company's stock valued at $67,000 after buying an additional 982 shares during the period. Virtus Fund Advisers LLC raised its stake in Collegium Pharmaceutical by 30.5% in the fourth quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company's stock worth $69,000 after buying an additional 565 shares in the last quarter. Finally, Nisa Investment Advisors LLC lifted its holdings in Collegium Pharmaceutical by 14.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company's stock worth $71,000 after buying an additional 316 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.